[go: up one dir, main page]

DK3009428T3 - Heterocyklisk diamino-carboxamid-forbindelse - Google Patents

Heterocyklisk diamino-carboxamid-forbindelse Download PDF

Info

Publication number
DK3009428T3
DK3009428T3 DK15189570.3T DK15189570T DK3009428T3 DK 3009428 T3 DK3009428 T3 DK 3009428T3 DK 15189570 T DK15189570 T DK 15189570T DK 3009428 T3 DK3009428 T3 DK 3009428T3
Authority
DK
Denmark
Prior art keywords
vol
patent document
compound
cancer
alk
Prior art date
Application number
DK15189570.3T
Other languages
English (en)
Inventor
Itsuro Shimada
Kazuo Kurosawa
Takahiro Matsuya
Kazuhiko Iikubo
Yutaka Kondoh
Akio Kamikawa
Hiroshi Tomiyama
Yoshinori Iwai
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3009428(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK3009428T3 publication Critical patent/DK3009428T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (3)

1. Forbindelse eller et salt deraf til anvendelse i en fremgangsmåde til at forebygge og/eller behandle akut myeloid leukæmi eller atypisk kronisk myeloid leukæmi, hvor forbindelsen er: 6-et hyl-3-({ 3-methoxy-4-[4-(4-methylpiperazin-1 -y I) piperidin-1 -yI] phenyl} amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazin-2-carboxamid.
2. Forbindelsen eller et salt deraf til anvendelse ifølge krav 1, hvor forbindelsen eller et salt deraf er: 6-ethyl-3-({ 3-methoxy-4-[4-(4-methylpiperazin-1 -yl)piperidin-1 -yl] phenyl} amino)-5-(tetrahydro-2FI-pyran-4-ylamino)pyrazin-2-carboxamid-hemifumarsyresalt.
3. Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 1 til 2, hvilken er anvendt i en fremgangsmåde til at forebygge og/eller behandle mutant FLT3 polynukleotid-positiv akut myeloid leukæmi, FLT3 fusion polynukleotid-positiv atypisk kronisk myeloid leukæmi, akut myeloid leukæmi med FLT3 intern tandemduplikationsmutation og/eller akut myeloid leukæmi med FLT3 aktiv punktmutation.
DK15189570.3T 2009-05-08 2010-05-06 Heterocyklisk diamino-carboxamid-forbindelse DK3009428T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009113936 2009-05-08
EP10772177.1A EP2428508B9 (en) 2009-05-08 2010-05-06 Diamino heterocyclic carboxamide compound

Publications (1)

Publication Number Publication Date
DK3009428T3 true DK3009428T3 (da) 2018-03-26

Family

ID=43050157

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15189570.3T DK3009428T3 (da) 2009-05-08 2010-05-06 Heterocyklisk diamino-carboxamid-forbindelse
DK10772177.1T DK2428508T3 (da) 2009-05-08 2010-05-06 Diamino heterocyklisk carboxamid-forbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10772177.1T DK2428508T3 (da) 2009-05-08 2010-05-06 Diamino heterocyklisk carboxamid-forbindelse

Country Status (28)

Country Link
US (2) US8969336B2 (da)
EP (2) EP3009428B1 (da)
JP (1) JP5364159B2 (da)
KR (1) KR101614572B1 (da)
CN (1) CN102421761B (da)
AU (1) AU2010245545B2 (da)
BR (1) BRPI1011838B8 (da)
CA (1) CA2760061C (da)
CY (3) CY1117546T1 (da)
DK (2) DK3009428T3 (da)
ES (2) ES2559230T3 (da)
FR (1) FR20C1003I2 (da)
HR (2) HRP20151435T8 (da)
HU (3) HUE026647T2 (da)
IL (1) IL216132A (da)
LT (2) LT3009428T (da)
LU (1) LUC00147I2 (da)
MX (1) MX2011011875A (da)
NL (1) NL301028I2 (da)
NO (2) NO3009428T3 (da)
PL (2) PL3009428T3 (da)
PT (2) PT2428508E (da)
RS (2) RS54552B1 (da)
SI (2) SI2428508T1 (da)
SM (2) SMT201800237T1 (da)
TW (1) TWI484961B (da)
WO (1) WO2010128659A1 (da)
ZA (1) ZA201108642B (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2536584C2 (ru) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3521291A1 (en) 2010-05-20 2019-08-07 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
AU2011289604C1 (en) 2010-08-10 2016-04-21 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
WO2012061415A1 (en) * 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TWI545115B (zh) 2010-11-01 2016-08-11 阿維拉製藥公司 雜環化合物及其用途
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
CN102285969B (zh) * 2011-06-28 2013-06-19 山东大学 N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用
AU2012298884B2 (en) 2011-08-23 2017-11-16 Foundation Medicine, Inc. Novel KIF5B-RET fusion molecules and uses thereof
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
AU2012340555B2 (en) 2011-11-23 2016-10-20 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
EA026353B1 (ru) * 2012-01-17 2017-03-31 Астеллас Фарма Инк. Соединение пиразинкарбоксамида
PL2825042T3 (pl) 2012-03-15 2019-02-28 Celgene Car Llc Sole inhibitora kinazy receptora czynnika wzrostu naskórka
MX356753B (es) 2012-03-15 2018-06-12 Celgene Avilomics Res Inc Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
JP6359020B6 (ja) * 2012-11-06 2018-08-15 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド Ａｌｋキナーゼ阻害剤
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
CA2900012A1 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN104262328B (zh) * 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
PE20160658A1 (es) 2013-10-11 2016-08-05 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
SG11201602387RA (en) * 2013-10-21 2016-05-30 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
AU2014360446A1 (en) * 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3091984B1 (en) 2014-01-09 2020-04-22 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Substituted benzoxazine and related compounds
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
RS60150B1 (sr) * 2014-02-04 2020-05-29 Astellas Pharma Inc Medicinska kompozicija koja obuhvata diamino heterociklično jedinjenje karboksamida kao aktivni sastojak
CN104016977B (zh) * 2014-06-13 2016-06-22 山东大学 一种取代噻二嗪二酮类衍生物及其制备方法与应用
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
ES2882954T3 (es) 2014-12-16 2021-12-03 Signal Pharm Llc Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel
BR112017012795A2 (pt) 2014-12-16 2018-01-02 Signal Pharmaceuticals, Llc Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
ES2940306T3 (es) 2015-07-03 2023-05-05 Astellas Pharma Inc Composición farmacéutica estable para administración oral
KR20180041135A (ko) 2015-07-16 2018-04-23 어레이 바이오파마 인크. Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
CN105001096B (zh) * 2015-07-21 2017-07-21 沈阳化工研究院有限公司 一种制备4‑氨基‑n‑烷基苄胺的方法
MX385379B (es) 2015-07-24 2025-03-18 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilciclohexanol e intermedios utiles en este.
WO2017078049A1 (ja) * 2015-11-04 2017-05-11 アステラス製薬株式会社 ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び／又は、免疫活性化用医薬組成物
JP6885390B2 (ja) 2016-02-26 2021-06-16 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
CN106083821B (zh) * 2016-06-22 2019-01-11 上海皓元生物医药科技有限公司 一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20200171022A1 (en) 2017-05-17 2020-06-04 Inserm (Institut National De La Santé Et Da La Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
JP7156287B2 (ja) 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
EP3741753A4 (en) * 2018-03-28 2021-03-31 Shenzhen TargetRx, Inc. SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND COMPOSITION CONTAINING THE COMPOUND AND ITS USE
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
WO2020063856A1 (zh) 2018-09-30 2020-04-02 南京明德新药研发有限公司 作为flt3和axl抑制剂的3,9-二氮杂螺[5,5]十一烷类化合物
KR102850357B1 (ko) 2018-10-22 2025-08-27 알루미스 인크. Tyk2 억제제 및 이의 용도
WO2020184670A1 (ja) 2019-03-13 2020-09-17 大塚製薬株式会社 二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法
MY204603A (en) 2019-04-03 2024-09-05 Astellas Pharma Inc Pharmaceutical composition
US20230141887A1 (en) * 2020-03-30 2023-05-11 Medshine Discovery Inc. Crystal form of diazaspiropyran compound
CN111423387B (zh) * 2020-05-11 2022-03-08 苏州康纯医药科技有限公司 一种Gilteritinib关键中间体的制备方法
MX2022013397A (es) * 2020-06-01 2022-12-13 Wigen Biomedicine Tech Shanghai Co Ltd Nuevo compuesto de pirazina.
WO2022009235A1 (en) * 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Process for the preparation of gilteritinib fumarate
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN112225703B (zh) * 2020-09-28 2022-03-11 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
CN117355508A (zh) * 2020-10-12 2024-01-05 西藏海思科制药有限公司 一种杂环衍生物及其在医药上的应用
WO2023027966A1 (en) * 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of FLT3
WO2023178094A2 (en) * 2022-03-14 2023-09-21 Purdue Research Foundation Spleen tyrosine kinase inhibitor, composition, and methods of use
WO2023225005A1 (en) * 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
CN115124590B (zh) * 2022-07-05 2024-10-22 武汉大学中南医院 一种靶向降解flt3-itd突变蛋白的protac类化合物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5107900A (en) 1999-06-09 2000-12-28 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2008013499A (ja) 2006-07-06 2008-01-24 Sankyo Co Ltd ５−シアノニコチンアミド誘導体
WO2008016660A2 (en) * 2006-08-02 2008-02-07 Xanthus Pharmaceuticals, Inc. Imidazoacridine compounds for treating leukemias
US20080070930A1 (en) 2006-08-24 2008-03-20 Huang Kenneth H Pyrimidine and Pyrazine Derivatives
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
MX2009006081A (es) 2006-12-08 2009-06-17 Irmc Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
EP2109605B1 (en) 2006-12-22 2013-02-20 Boehringer Ingelheim International GmbH 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
NZ582485A (en) 2007-07-17 2012-05-25 Rigel Pharmaceuticals Inc Cyclic amine substituted pyrimidinediamines as pkc inhibitors
US7981903B2 (en) 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
US8426417B2 (en) 2007-09-28 2013-04-23 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
US20090270418A1 (en) 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
US8518931B2 (en) 2008-04-07 2013-08-27 Irm Llc Compounds and compositions as kinase inhibitors
MX2010010968A (es) 2008-04-07 2010-10-26 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
WO2009136995A2 (en) * 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
EA024109B1 (ru) * 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
BRPI0908637B8 (pt) 2008-05-21 2021-05-25 Ariad Pharma Inc composto e composição farmacêutica do mesmo

Also Published As

Publication number Publication date
CN102421761B (zh) 2014-06-18
NL301028I2 (nl) 2020-04-15
RU2011149799A (ru) 2013-06-20
SI3009428T1 (en) 2018-04-30
PT3009428T (pt) 2018-04-02
ES2667706T3 (es) 2018-05-14
HRP20151435T1 (hr) 2016-03-25
EP3009428A1 (en) 2016-04-20
KR20120007523A (ko) 2012-01-20
CY1117546T1 (el) 2017-04-26
DK2428508T3 (da) 2016-02-01
ZA201108642B (en) 2013-02-27
HUS2000005I1 (hu) 2020-03-30
EP3009428B1 (en) 2018-02-21
BRPI1011838A2 (pt) 2018-02-06
SMT201800237T1 (it) 2018-09-13
BRPI1011838B8 (pt) 2021-05-25
EP2428508B1 (en) 2015-12-16
PL2428508T3 (pl) 2016-05-31
FR20C1003I1 (da) 2020-03-20
IL216132A0 (en) 2012-01-31
US20140371196A1 (en) 2014-12-18
EP2428508A4 (en) 2012-11-28
NO3009428T3 (da) 2018-07-21
HUE038515T2 (hu) 2018-10-29
SMT201600075B (it) 2016-04-29
CN102421761A (zh) 2012-04-18
NL301028I1 (nl) 2020-01-22
HRP20151435T8 (hr) 2016-07-01
CA2760061C (en) 2017-02-28
TWI484961B (zh) 2015-05-21
LT3009428T (lt) 2018-04-10
EP2428508B9 (en) 2016-04-20
KR101614572B1 (ko) 2016-04-21
AU2010245545B2 (en) 2014-09-11
IL216132A (en) 2015-10-29
ES2559230T3 (es) 2016-02-11
FR20C1003I2 (fr) 2020-12-04
LUC00147I2 (da) 2021-02-12
PT2428508E (pt) 2016-02-29
US20120040968A1 (en) 2012-02-16
SI2428508T1 (sl) 2016-04-29
LTPA2020002I1 (lt) 2020-02-10
MX2011011875A (es) 2011-12-08
EP2428508A1 (en) 2012-03-14
US9487491B2 (en) 2016-11-08
JP5364159B2 (ja) 2013-12-11
TW201105326A (en) 2011-02-16
HUE026647T2 (en) 2016-07-28
RU2526253C2 (ru) 2014-08-20
CA2760061A1 (en) 2010-11-11
JPWO2010128659A1 (ja) 2012-11-01
LTC2428508I2 (lt) 2020-12-28
AU2010245545A1 (en) 2011-11-03
NO2020001I1 (no) 2020-01-16
HRP20180368T1 (hr) 2018-04-06
RS57045B1 (sr) 2018-05-31
CY2020004I1 (el) 2020-05-29
WO2010128659A1 (ja) 2010-11-11
CY2020004I2 (el) 2020-05-29
BRPI1011838B1 (pt) 2021-03-16
HUS000511I2 (hu) 2021-03-29
PL3009428T3 (pl) 2018-07-31
LUC00147I1 (da) 2020-02-10
CY1120367T1 (el) 2019-07-10
US8969336B2 (en) 2015-03-03
HK1219105A1 (en) 2017-03-24
RS54552B1 (sr) 2016-06-30

Similar Documents

Publication Publication Date Title
DK3009428T3 (da) Heterocyklisk diamino-carboxamid-forbindelse
JP7402549B2 (ja) Ｃｘｃｒ４阻害剤およびその使用
KR101323566B1 (ko) 디(아릴아미노)아릴 화합물
EP3584239B1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
JP2021176819A (ja) キナゾリン化合物を有効成分とする医薬組成物
JP2014005206A (ja) アリールアミノヘテロ環カルボキサミド化合物
JP2021176820A (ja) キナゾリン化合物を有効成分とする医薬組成物
CN117285590A (zh) 一种化合物、其制备方法、包括其的组合物及其应用
US12459895B2 (en) MEK inhibitors and uses thereof
AU2018234985B2 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
BR112021004527A2 (pt) kits e métodos para tratamento contra câncer
WO2024092116A1 (en) Combination of tead inhibitors and egfr inhibitors and uses thereof
HK1219105B (en) Diamino heterocyclic carboxamide compound
JP2018527321A (ja) クロロベンゼン置換されたアザアリール化合物
CN113354630B (zh) 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用
RU2526253C9 (ru) Диаминогетероциклическое карбоксамидное соединение
HK40050670A (en) Substituted piperidines as cxcr4-inhibitors
JP2015163592A (ja) 抗癌剤の併用による癌治療方法
HK40006048B (en) Cxcr4 inhibitors and uses thereof
HK40006048A (en) Cxcr4 inhibitors and uses thereof
JP2015163591A (ja) 抗癌剤の併用による癌治療方法